TAIHO PHARMA

Exploring hidden
possibilities for
people awaiting
new medicines

About Taiho

Becoming a truly global specialty pharma that meets the expectations of patients worldwide.

Our Business

Taiho Pharmaceutical creates innovative, highly valuable new drugs to support patients and the advancement of medicine, seeking to contribute to smiles and health for people all around the world.

News Releases

July 28, 2020

Taiho Pharmaceutical Launches Anticancer Agent LONSURF^® (brand name in Japan) in China for Treatment of Colorectal Cancer
July 08, 2020

Taiho announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI^®, an oral hypomethylating agent (HMA) therapy for MDS and CMML（PDF：514.9 KB）
June 15, 2020

Taiho Pharmaceutical Submits Application for Additional Dosage and Administration of 5-HT₃ Receptor Antagonist　Aloxi_® for Pediatric Patients in Japan
February 27, 2020

Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences' Anti-PD-1 Antibody in Asia
January 06, 2020

Taiho, Astex and MSD Establish Strategic Oncology Collaboration

Information

July 12, 2018

Announcement of Support from Otsuka Holdings and Its Group Companies in the Aftermath of Severe Storms in Japan（PDF：165.9 KB）